Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Significant Decrease in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 66,000 shares, a decrease of 44.8% from the October 15th total of 119,500 shares. Based on an average daily volume of 130,800 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are sold short.

Hedge Funds Weigh In On Bolt Biotherapeutics

A hedge fund recently bought a new stake in Bolt Biotherapeutics stock. Assenagon Asset Management S.A. purchased a new position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,488 shares of the company’s stock, valued at approximately $26,000. Assenagon Asset Management S.A. owned approximately 0.09% of Bolt Biotherapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 86.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.50.

Bolt Biotherapeutics Trading Up 1.3 %

BOLT stock traded up $0.01 during midday trading on Wednesday, reaching $0.65. The company’s stock had a trading volume of 18,856 shares, compared to its average volume of 165,183. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.28 and a current ratio of 4.28. The stock has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.74. Bolt Biotherapeutics has a 1 year low of $0.55 and a 1 year high of $1.56. The firm has a market capitalization of $24.87 million, a price-to-earnings ratio of -0.37 and a beta of 0.92.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The firm had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $1.02 million. Bolt Biotherapeutics had a negative net margin of 592.57% and a negative return on equity of 61.40%. On average, equities research analysts predict that Bolt Biotherapeutics will post -1.52 EPS for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.